Biohit Oyj (LTS:0DRP) Marketable Securities: €1.31 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0DRP Biohit Oyj LTS:0DRP
78 GF Score
Price €2.76
GF Value €2.71
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Biohit Oyj Marketable Securities?

Biohit Oyj LTS:0DRP -2.82% 78 Marketable Securities is €1.31 Mil as of Dec. 2025. GuruFocus rates LTS:0DRP with a GF Score™ of 78/100 and a GF Value™ of €2.71 (Fairly Valued). The stock has 3 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Biohit Oyj's Marketable Securities for the quarter that ended in Dec. 2025 was €1.31 Mil.

Biohit Oyj's annual Marketable Securities declined from Dec. 2023 (€3.54 Mil) to Dec. 2024 (€2.97 Mil) and declined from Dec. 2024 (€2.97 Mil) to Dec. 2025 (€1.31 Mil).

Biohit Oyj  (LTS:0DRP) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Biohit Oyj Marketable Securities Related Terms

Biohit Oyj Marketable Securities Historical Data

* Premium members only.

The historical data trend for Biohit Oyj's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biohit Oyj Marketable Securities Chart

Biohit Oyj Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.41 4.11 3.54 2.97 1.31

Biohit Oyj Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.54 3.20 2.97 1.30 1.31
LTS:0DRP
78GF Score
Biohit Oyj LTS:0DRP
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biohit Oyj Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of €1.31 Mil mean?
Biohit Oyj (LTS:0DRP) has a Marketable Securities of €1.31 Mil as of Dec. 2025. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Biohit Oyj and its competitors.
Is Biohit Oyj's Marketable Securities too high?
Biohit Oyj's current Marketable Securities is €1.31 Mil. Overall, Biohit Oyj has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biohit Oyj's Marketable Securities compare to ABT and SYK?
Biohit Oyj's Marketable Securities of €1.31 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Medical Devices & Instruments company?
A good Marketable Securities depends on the Medical Devices & Instruments industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Biohit Oyj and its competitors. Biohit Oyj's current Marketable Securities is €1.31 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biohit Oyj stock overvalued right now?
Based on GuruFocus' analysis, Biohit Oyj (LTS:0DRP) is currently considered Fairly Valued. The stock's GF Value™ is €2.71, compared to a current price of €2.76 — trading 1.8% above its estimated fair value. The current Marketable Securities is €1.31 Mil. Biohit Oyj's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Biohit Oyj (LTS:0DRP), the current Marketable Securities is €1.31 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biohit Oyj (LTS:0DRP) Overvalued in 2026?

Based on GuruFocus' analysis, Biohit Oyj stock appears to be overvalued. The current stock price of €2.76 is trading 1.8% above its estimated GF Value™ of €2.71. GuruFocus considers Biohit Oyj to be Fairly Valued.

Key valuation signals for LTS:0DRP:

  • Marketable Securities: €1.31 Mil
  • GF Value™: €2.71 vs. price of €2.76 (1.8% above fair value)
  • GF Score™: 78/100 with 3 warning signs

No single metric tells the full story. See the LTS:0DRP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biohit Oyj Business Description

Other Exchanges BIOBV:Finland
Address Laippatie 1, Helsinki, FIN, 00880
Biohit Oyj is a globally operating Finnish biotechnology company that develops diagnostic and other health products. Its products include GastroPanel quick test assesses the structure and function of the stomach lining; ColonView quick test is an immunochemical fecal occult blood test (FIT) developed; Acetium capsules protect the stomach lining from carcinogenic acetaldehyde, especially in people with acid-free stomachs. The company's product portfolio consists of diagnostic tests, analysis systems, products binding carcinogenic acetaldehyde into a harmless compound and monoclonal antibodies.
78GF Score

Get the complete analysis for LTS:0DRP

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.76
Price
€2.71
GF Value